It's a knock out: eIF4E-specific anti-sense oligonucleotides knock down cancer

A new study in the September issue of the Journal of Clinical Investigation by Jeremy Graff and colleagues from Eli Lilly and Company demonstrates the anti-cancer effect of a new therapeutic (eIF4E-specific anti-sense oligonucleotides) in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers.

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <em> <strong> <cite><p><br><i><b><center><ul><li><div><html5:figure><html5:figcaption>
  • Lines and paragraphs break automatically.

More information about formatting options

CAPTCHA
Sorry, we know you're not a spambot, but they're out there